Drug Database
Back to search

Poland· PL-100056339

Provera

A medroxyprogesterone product containing medroxyprogesteroni acetas, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 9 of our 19 countries.

ATC G03DA02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedProveraATCG03DA02REGISTER NO.PL-100056339PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about medroxyprogesteroni acetasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Medroxyprogesterone is registered in 9 of 19 countries.

Countries holding a registration under ATC G03DA02 (medroxyprogesterone), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose
Search medroxyprogesterone products by name

Medroxyprogesterone · ATC G03DA02

9 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Medroxyprogesteroni acetas
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
G03DA02
ATC class
Medroxyprogesterone
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990236411

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

241 interactions on record for medroxyprogesterone.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check medroxyprogesterone against other medicinesHow interaction checks work

Medroxyprogesterone · interactions on record

241 records

  • 21 severe
  • 213 moderate
  • 7 minor

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • BosentanC02KX01severe
  • GriseofulvinD01AA08severe
  • GriseofulvinD01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Medroxyprogesterone in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All medroxyprogesterone products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Depocon, Farlutal
  • Belgium · Depo-Provera, Provera
  • Bulgaria · Фарлутал
  • Czechia · Depo-Provera, Provera
  • Germany · Depo-Clinovir, Mpa
  • Denmark · Depo-Provera, Provera
  • Estonia · Farlutal
  • Spain · Depo-Progevera, Progevera
  • Finland · Farlutal, Provera
  • France · Depo Prodasone, Depo Provera
  • United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
  • Croatia · Provera
  • Hungary · Depo-Provera, Provera
  • Ireland · Depo-Provera, Provera
  • Iceland · Depo-Provera
  • Italy · Depo-Provera, Farlutal
  • Luxembourg · Depo-Provera, Provera
  • Latvia · Depo-Provera
  • Netherlands · Depo-Provera, Provera
  • Norway · Depo-Provera, Provera
  • Portugal · Depo-Provera 150
  • Sweden · Depo-Provera, Provera

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6aaa8150-808e-482a-9d8b-b78fbd53d87f
GET /v1/drugs/6aaa8150-808e-482a-9d8b-b78fbd53d87f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "05909990236411 ¦ Rp ¦ 8433\n30 tabl.",
  "substance": "Medroxyprogesteroni acetas 5 mg",
  "common_name": "Medroxyprogesteroni acetas",
  "pl_product_id": "100056339",
  "pozwolenie_nr": "02364",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about medroxyprogesterone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console